Methods for Diagnosing Breast and Lung Cancer Using miR-210 and miR-213
The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.
1 .- 33 . (canceled)
34 . A method of diagnosing whether a subject has, or is at risk for developing, breast cancer or lung cancer, comprising:
a.) comparing the level of at least miR-210 gene product in a test sample to a control level of at least miR-210 gene products; and
b.) diagnosing whether the subject has, or is at risk for developing, breast cancer or lung cancer, if the level of at least miR-210 gene product in the test sample from the subject is greater than the level of miR-210 gene product of the control.
35 . A method of diagnosing whether a subject has, or is at risk for developing, breast cancer or lung cancer, comprising:
a.) reverse transcribing at least miR-210 from a test sample obtained from the subject to provide at least miR-210 target oligonucleotides;
b.) hybridizing at least the miR-210 target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides that include at least miR-210 RNA specific probe oligonucleotides to provide a hybridization profile for the test sample;
c.) comparing the test sample hybridization profile to at least one control hybridization profile; and
d.) diagnosing whether the subject has, or is at risk for developing, breast cancer or lung cancer if the level of at least miR-210 gene product in the test sample from the subject is greater than the level of miR-210 gene product of the control.
36 . The method of claim 34 , which further comprises comparing the level of at least one additional miR gene product in a test sample from the subject to a control level of the miR gene product, wherein the at least one additional miR gene product is selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
37 . The method of claim 34 , which further comprises comparing the level of at least two additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least two additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
38 . The method of claim 34 , which further comprises comparing the level of at least three additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least three additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
39 . The method of claim 34 , which further comprises comparing the level of at least four additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least four additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
40 . The method of claim 34 , which further comprises comparing the level of at least five additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least five additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
41 . The method of claim 34 , which further comprises measuring the level of at least one miR-213 gene product.
42 . The method of claim 34 , wherein the cancer is breast cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-125b-1; miR125b-2; miR-145; and miR-21.
43 . The method of claim 34 , wherein the cancer is breast cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-21; miR-29b-2; miR-146; miR-125b-2; miR-125b-1; miR-10b; miR-145; miR-181a; miR-140; miR-213; miR-29a prec; miR-181b-1; miR-199b; miR-29b-1; miR-130a; miR-155; let-7a-2; miR-205; miR-29c; miR-224; miR-100; miR-31; miR-30c; miR-17-5p; miR-210; miR-122a; and miR-16-2.
44 . The method of claim 34 , wherein the cancer is lung cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-21; miR-205; miR-200b; miR-9-1; miR-210; miR-148; miR-141; miR-132; miR-215; miR-128b; let-7g; miR-16-2; miR-129-1/2 prec; miR-126; miR-142-as; miR-30d; miR-30a-5p; miR-7-2; miR-199a-1; miR-127; miR-34a prec; miR-34a; miR-136; miR-202; miR-196-2; miR-199a-2; let-7a-2; miR-124a-1; miR-149; miR-17-5p; miR-196-1 prec; miR-10a; miR-99b prec; miR-196-1; miR-199b; miR-191; miR-195; and miR-155.
45 . A method of diagnosing whether a subject has, or is at risk for developing, breast cancer or lung cancer, comprising:
a.) comparing the level of at least miR-213 gene product in a test sample to a control level of at least miR-213 gene products; and
b.) diagnosing whether the subject has, or is at risk for developing, breast cancer or lung cancer, if the level of at least miR-213 gene product in the test sample from the subject is greater than the level of miR-213 gene product of the control.
46 . A method of diagnosing whether a subject has, or is at risk for developing, breast cancer or lung cancer, comprising:
a.) reverse transcribing at least miR-213 from a test sample obtained from the subject to provide at least miR-213 target oligonucleotides;
b.) hybridizing at least the miR-213 target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides that include at least miR-213 RNA specific probe oligonucleotides to provide a hybridization profile for the test sample;
c.) comparing the test sample hybridization profile to at least one control hybridization profile; and
d.) diagnosing whether the subject has, or is at risk for developing, a breast cancer or lung cancer, if the level of at least miR-213 gene product in the test sample from the subject is greater than the level of miR-213 gene product of the control.
47 . The method of claim 45 , which further comprises comparing the level of at least one additional miR gene product in a test sample from the subject to a control level of the miR gene product, wherein the at least one additional miR gene product is selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
48 . The method of claim 45 , which further comprises comparing the level of at least two additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least two additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
49 . The method of claim 45 , which further comprises comparing the level of at least three additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least three additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
50 . The method of claim 45 , which further comprises comparing the level of at least four additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least four additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
51 . The method of claim 45 , which further comprises comparing the level of at least five additional miR gene products in a test sample from the subject to a control level of the corresponding miR gene products, wherein the at least five additional miR gene products are selected from the group consisting of: miR-21; miR-17-5p; miR-191; miR-29b-2; miR-223; miR-128b; miR-199a-1; miR-24-1; miR-24-2; miR-146; miR-155; miR-181b-1; miR-20a; miR-107; miR-32; miR-92-2; miR-214; miR-30c; miR-25; miR-221; and miR-106a.
52 . The method of claim 45 , which further comprises measuring the level of at least one miR-210 gene product.
53 . The method of claim 45 , wherein the cancer is breast cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-125b-1; miR125b-2; miR-145; and miR-21.
54 . The method of claim 45 , wherein the cancer is breast cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-21; miR-29b-2; miR-146; miR-125b-2; miR-125b-1; miR-10b; miR-145; miR-181a; miR-140; miR-213; miR-29a prec; miR-181b-1; miR-199b; miR-29b-1; miR-130a; miR-155; let-7a-2; miR-205; miR-29c; miR-224; miR-100; miR-31; miR-30c; miR-17-5p; miR-210; miR-122a; and miR-16-2.
55 . The method of claim 45 , wherein the cancer is lung cancer and which further comprises measuring the level of at least one miR gene product selected from the group consisting of: miR-21; miR-205; miR-200b; miR-9-1; miR-210; miR-148; miR-141; miR-132; miR-215; miR-128b; let-7g; miR-16-2; miR-129-1/2 prec; miR-126; miR-142-as; miR-30d; miR-30a-5p; miR-7-2; miR-199a-1; miR-127; miR-34a prec; miR-34a; miR-136; miR-202; miR-196-2; miR-199a-2; let-7a-2; miR-124a-1; miR-149; miR-17-5p; miR-196-1 prec; miR-10a; miR-99b prec; miR-196-1; miR-199b; miR-191; miR-195; and miR-155.